Value Insider Season 1 Episode 5: What Other Aspects of Value May Be Relevant? (Societal Impact) [Podcast]

Value Insider Season 1 Episode 5: What Other Aspects of Value May Be Relevant? (Societal Impact) [Podcast]

Louis P Garrison,1 Elisabeth Sophia Hartgers-Gubbels,2 Michael Chambers3 1School of Pharmacy, University of Washington, Seattle, WA, USA; 2Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 3MC Healthcare Evaluation, London, UKCorrespondence: Elisabeth Sophia Hartgers-Gubbels, Boe...

Full description

Bibliographic Details
Main Authors:	Garrison LP, Hartgers-Gubbels ES, Chambers M
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-11-01
Series:	International Journal of General Medicine
Subjects:	market access healthcare reimbursement health technology assessment (hta) value demonstration health economics and outcomes research payer
Online Access:	https://www.dovepress.com/value-insider-season-1-episode-5-what-other-aspects-of-value-may-be-re-peer-reviewed-fulltext-article-IJGM

Similar Items

Value Insider Season 1 Episode 6: How Will Market Access and Value Demonstration Evolve? (Future Outlook) [Podcast]
by: Kanavos PG, et al.
Published: (2022-12-01)

Value Insider Season 1 Episode 2: How to Measure Quality of Life and Utility? (QoL) [Podcast]
by: Devlin NJ, et al.
Published: (2022-10-01)

Value Insider Season 1 Episode 1: The Importance of Payers and HTA: How Did We End Up Here? (Introduction to Value) [Podcast]
by: Drummond MF, et al.
Published: (2022-09-01)

Value Insider Season 1 Episode 3: How Does Budget Impact and Affordability in Healthcare Work? (BI and Affordability) [Podcast]
by: Sullivan SD, et al.
Published: (2022-10-01)

Value Insider Season 1 Episode 4: How are Costs Measured, and How are CEAs Constructed and Used? (CEA) [Podcast]
by: Rutten-van Mölken MPMH, et al.
Published: (2022-11-01)

Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports
by: Joost J. Enzing, et al.
Published: (2022-08-01)

A review of 25 years of National Institute of Health and Care Excellence decision making
by: Xin Zhang, et al.
Published: (2024-07-01)

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
by: Virginia Ronco, et al.
Published: (2021-12-01)

Comparing access to orphan medicinal products in Europe
by: Bernarda Zamora, et al.
Published: (2019-05-01)

Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States
by: Lauren K. Lemke, et al.
Published: (2023-08-01)

International practices in health technology assessment and public financing of digital health technologies: recommendations for Hungary
by: Fruzsina Mezei, et al.
Published: (2023-08-01)

HTA regulation: how is Italy moving?
by: Francesca Patarnello
Published: (2024-03-01)

Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries
by: Alessandra Blonda, et al.
Published: (2022-01-01)

The role of HTA agencies in Poland and in the world
by: Aneta Katarzyna Mela
Published: (2020-07-01)

Reimbursement decision-making system in Poland systematically compared to other countries
by: Aneta Mela, et al.
Published: (2023-10-01)

Influencing Factors of Health Technology Assessment to Orphan Drugs: Empirical Evidence in England, Scotland, Canada, and Australia
by: Na Zhou, et al.
Published: (2022-06-01)

Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
by: Szczepan Jakubowski, et al.
Published: (2024-03-01)

Values-Based Foundation for a U.S. Single Payer Health System Model
by: Walter Markowitz, et al.
Published: (2021-04-01)

Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies
by: Pascale Lehoux, et al.
Published: (2017-09-01)

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
by: Oriol Solà-Morales, et al.
Published: (2019-01-01)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
by: Alessandra Blonda, et al.
Published: (2022-07-01)

Technology Assessment vs. Technology Appraisal—How to Strengthen the Science/Value Dichotomy with EU HTA?
by: Sandro Gsteiger, et al.
Published: (2024-11-01)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
by: Nicola Allen, et al.
Published: (2017-06-01)

CAR-T Cells in Canada; Perspective on How to Ensure We Get Our Value’s Worth
by: Pierre J. A. Villeneuve, et al.
Published: (2023-04-01)

Value-Based Payment System and Consideration of Radiology
by: Choong Wook Lee
Published: (2024-11-01)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
by: Krzysztof Piotr Malinowski, et al.
Published: (2018-11-01)

Assessment and value of drugs: report of the focus groups from the XXII National Conference on Pharmaceuticals
by: Valentina Drago, et al.
Published: (2025-02-01)

Perceptions of indirect treatment comparisons as an evidence base in oncology decision-making: results of an international survey of health technology assessment and payer decision-makers
by: Ioannis Katsoulis, et al.
Published: (2024-11-01)

Characterization and analysis of the basic elements of health payment mechanisms and their most frequent types
by: Daniela Paredes-Fernández, et al.
Published: (2020-10-01)

Patient and Payer Preferences for Additional Value Criteria
by: Ivett Jakab, et al.
Published: (2021-06-01)

Val (EU) xit: do we need an international ISPOR value flower?
by: Sreeram V Ramagopalan, et al.
Published: (2024-07-01)

The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies
by: Grammati Sarri, et al.
Published: (2024-08-01)

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
by: Ting Wang, et al.
Published: (2022-07-01)

A roadmap toward implementing health technology assessment in Egypt
by: Ahmad Nader Fasseeh, et al.
Published: (2022-12-01)

Health Technology Assessment (HTA) and health policy making: a narrative review
by: Anuji Upekshika Gamage, et al.
Published: (2020-11-01)

Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years
by: Aneta Mela, et al.
Published: (2020-08-01)

Opportunities and Challenges in Cross-Country Collaboration: Insights from the Beneluxa Initiative
by: Zilke Claessens, et al.
Published: (2024-07-01)

Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries
by: Juan Carlos Rejon-Parrilla, et al.
Published: (2023-11-01)

Obstacles to Prosthetic Care—Legal and Ethical Aspects of Access to Upper and Lower Limb Prosthetics in Germany and the Improvement of Prosthetic Care from a Social Perspective
by: Martina F. Baumann, et al.
Published: (2020-01-01)

Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
by: Jesper Jørgensen, et al.
Published: (2020-01-01)